Cancer heterogeneity determined by functional proteomics
(2017) In Seminars in Cell and Developmental Biology 64. p.132-142- Abstract
Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling... (More)
Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.
(Less)
- author
- Szász, Marcell LU ; Gyorffy, Balázs and Marko-Varga, György LU
- organization
- publishing date
- 2017-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biomarkers, Cancer heterogeneity, Clinical study, Genomics, Multiple reaction monitoring (MRM), Parallel reaction monitoring (PRM), Proteomics, Single reaction monitoring (SRM)
- in
- Seminars in Cell and Developmental Biology
- volume
- 64
- pages
- 11 pages
- publisher
- Academic Press
- external identifiers
-
- pmid:27569188
- scopus:84995366730
- ISSN
- 1084-9521
- DOI
- 10.1016/j.semcdb.2016.08.026
- language
- English
- LU publication?
- yes
- id
- b16c224c-c8f0-4ecf-8b2a-cbf2e3c53662
- date added to LUP
- 2017-01-12 12:47:03
- date last changed
- 2024-01-04 20:36:36
@article{b16c224c-c8f0-4ecf-8b2a-cbf2e3c53662,
abstract = {{<p>Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry.First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development.An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients.In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.</p>}},
author = {{Szász, Marcell and Gyorffy, Balázs and Marko-Varga, György}},
issn = {{1084-9521}},
keywords = {{Biomarkers; Cancer heterogeneity; Clinical study; Genomics; Multiple reaction monitoring (MRM); Parallel reaction monitoring (PRM); Proteomics; Single reaction monitoring (SRM)}},
language = {{eng}},
pages = {{132--142}},
publisher = {{Academic Press}},
series = {{Seminars in Cell and Developmental Biology}},
title = {{Cancer heterogeneity determined by functional proteomics}},
url = {{http://dx.doi.org/10.1016/j.semcdb.2016.08.026}},
doi = {{10.1016/j.semcdb.2016.08.026}},
volume = {{64}},
year = {{2017}},
}